pdufa.bio

EMBLAVEO (aztreonam and avibactam)

Updated ยทnext FDA decision on the calendar

EMBLAVEO (aztreonam and avibactam) 1 FDA decision on record below. Every date links its source.

ABBV catalyst hub

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Feb 7, 2025 ✓ ApprovedABBV

Questions

When is EMBLAVEO (aztreonam and avibactam)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for EMBLAVEO (aztreonam and avibactam); 1 FDA decision is on record below.

What happened at EMBLAVEO (aztreonam and avibactam)'s most recent FDA decision?

On Feb 7, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has EMBLAVEO (aztreonam and avibactam) been approved by the FDA?

Yes. The FDA approved an application for EMBLAVEO (aztreonam and avibactam) on Feb 7, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.